Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has selected Japan’s Mitsubishi Tanabe Pharmaceutical Corp. to establish a co-promotion partnership for Moderna’s mRNA respiratory vaccine portfolio in the Japanese market. The agreement will encompass the promotion of Moderna’s COVID-19 vaccine, Spikevax, and aims to enhance access to Moderna’s vaccines in Japan, initiating the commercialization process.
Under the terms of the partnership, Moderna will maintain its focus on manufacturing, sales, medical education, and distribution of its vaccine portfolio, while Mitsubishi Tanabe will collaborate as a promotional partner. The agreement, as outlined in a press release, is set to run until 2029. Financial details of the deal were not disclosed.- Flcube.com
